Showing results (111-120 of 288) with videos related to
Sort By:
Pageof 29
Leukemia Research|July 1, 2022
Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center studyAvraham Frisch, Shlomzion Aumann, Tsila Zuckerman, et al.Blood Reviews|February 28, 2012
Hyperleukocytosis, leukostasis and leukapheresis: practice managementChezi Ganzel, Joanne Becker, Paul D Mintz, et al.Therapeutic Drug Monitoring|May 29, 2004
A simple approximation for busulfan dose adjustment in adult patients undergoing bone marrow transplantationErica Hoffer, Luiza Akria, Arek Tabak, et al.Thrombosis Research|May 24, 2005
Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patientsNajib Dally, Ron Hoffman, Nuhad Haddad, et al.Current Drug Safety|September 7, 2012
Pharmacokinetic and pharmacogenetic analysis of oral busulfan in stem cell transplantation: prediction of poor drug metabolism to prevent drug toxicityNorberto Krivoy, Tsila Zuckerman, Hela Elkin, et al.Annals of Hematology|June 22, 2022
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysisOfir Wolach, Avraham Frisch, Liat Shargian, et al.Blood Neoplasia|March 27, 2026
Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trialJames M Foran, Zhuoxin Sun, Selina M Luger, et al.Annals of Hematology|September 13, 2019
Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control studyTamar Berger, Uri Rozovski, Yakir Moshe, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2010
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopesYishai Ofran, Haesook T Kim, Vladimir Brusic, et al.Annals of Hematology|June 23, 2022
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysisShai Shimony, Jonathan Canaani, Eitan Kugler, et al.Pageof 29